Due to an association with Gleason score and tumor stage, the reported prevalence of PTEN loss in prostate cancer is variable across different cohorts and is reported in about 20% of primary and in about 40% of metastatic tumors [7, 8, 10, 11, 17–19]. Here, PTEN is linked to prostate carcinoma.